SNDX News and Press, Syndax Pharmaceuticals Inc.

2026-06-26 09:22:31 ET Following my article , " Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor ," Jazz Pharmaceuticals' ( JAZZ ) shares have risen 108.2%, outperforming the so-called "bellwether" for the biotech-focused investors, the iShares Biotechn...

2026-06-12 08:15:08 ET UBS analyst issues BUY recommendation for SNDX on June 12, 2026 10:53AM ET. The previous analyst recommendation was Buy. SNDX was trading at $17.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...

2026-06-11 08:57:50 ET Syndax ( SNDX ) is no longer simply a binary clinical-stage biotech company; it is a two-product commercial oncology company with increasing revenue, a substantial amount of remaining cash, and two product families that could have their greatest value as a res...

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML s...

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) ...

2026-06-10 13:12:10 ET Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call June 10, 2026 12:00 PM EDT... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript

2026-06-08 16:28:32 ET Syndax Pharmaceuticals, Inc. (SNDX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 2:00 PM EDT... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47...

2026-06-04 07:35:33 ET Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals prices $250M senior convertible notes

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million ag...

– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% vs historical benchmark of 51% – – Company also presented data highl...